Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control

Phase 3

Recruiting

Conditions: Breast Cancer

Interventions: Behavioral: patient-reported pain scores
Drug: Bupivacaine
Other: saline

First Posted Date: 2017-11-22

Last Posted Date: 2024-12-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 144

Registration Number: NCT03351348

Locations: 🇺🇸
Memorial Sloan Kettering Commack (Consent and follow-up only), Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Nassau (Consent and follow-up only), Uniondale, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester (Consent and follow-up only), Harrison, New York, United States

and more 4 locations

Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity

Completed

Conditions: Central Nervous System Lymphoma

Interventions: Diagnostic Test: Resting State fMRI (rsfMRI)
Other: Auditory Attention and Executive Functions Test
Other: Memory Test
Other: Motor Speed Test
Other: Self Reported Quality of Life Questionnaire

First Posted Date: 2017-11-17

Last Posted Date: 2022-08-08

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 14

Registration Number: NCT03342586

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Fulvestrant
Drug: Debio 1347

First Posted Date: 2017-11-17

Last Posted Date: 2022-11-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 10

Registration Number: NCT03344536

Locations: 🇺🇸
Memorioal Sloan Kettering Cancer Center, New York, New York, United States

A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma

Recruiting

Conditions: Pancreatitis
Pancreatic Diseases
Pancreatic Cyst
Pancreatic Cancer

Interventions: Diagnostic Test: Blood Draw
Diagnostic Test: Tumor Tissue Collection
Diagnostic Test: Cyst Fluid

First Posted Date: 2017-11-07

Last Posted Date: 2025-05-15

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 700

Registration Number: NCT03334708

Locations: 🇺🇸
Memorial Sloan Kettering Westchester (All protocol activities), Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Nassau (All protocol activities), Rockville Centre, New York, United States
🇺🇸
Weill Cornell Medical Center, New York, New York, United States

and more 10 locations

Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses

Recruiting

Conditions: Erdheim-Chester Disease

First Posted Date: 2017-11-01

Last Posted Date: 2023-12-11

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 250

Registration Number: NCT03329274

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New YorK, New York, United States

Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors

Completed

Conditions: Metastatic Melanoma

Interventions: Behavioral: EuroQoL EQ-5D-3L
Behavioral: EORTC QLQ-C30
Other: PRO-CTCAE
Behavioral: Fatigue severity score questionnaire
Behavioral: The COST
Behavioral: Physician information

First Posted Date: 2017-10-31

Last Posted Date: 2020-12-17

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 107

Registration Number: NCT03326973

Locations: 🇺🇸
Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States

and more 3 locations

Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma

Phase 2

Active, not recruiting

Conditions: Squamous Cell Carcinoma of the Neck
HPV-Associated Oropharyngeal Squamous Cell Carcinoma

Interventions: Diagnostic Test: F-FMISO PET/CT Scan
Radiation: 30 Gy over 3 weeks
Drug: Cisplatin
Drug: Carboplatin
Drug: 5Fluorouracil
Radiation: Proton Therapy

First Posted Date: 2017-10-27

Last Posted Date: 2025-01-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 316

Registration Number: NCT03323463

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States

and more 7 locations

Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma

Phase 1

Terminated

Conditions: Mesothelioma

Interventions: Drug: pevonedistat
Drug: Pemetrexed and cisplatin

First Posted Date: 2017-10-24

Last Posted Date: 2024-05-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 9

Registration Number: NCT03319537

Locations: 🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Nassau, Uniondale, New York, United States

and more 5 locations

Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites

Phase 4

Active, not recruiting

Conditions: Smoking Cessation

Interventions: Drug: Nicotine Lozenge
Drug: Nicotine Replacement Therapy (NRT)
Behavioral: Motivational Interviewing (MI)
Behavioral: Message Framing
Other: saliva sample

First Posted Date: 2017-10-20

Last Posted Date: 2025-02-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 807

Registration Number: NCT03315910

Locations: 🇺🇸
John Muir Health, Walnut Creek, California, United States
🇺🇸
WellStar Health System, LaGrange, Georgia, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 14 locations

Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis

Phase 2

Active, not recruiting

Conditions: AL Amyloidosis
Multiple Myeloma

Interventions: Drug: Siltuximab
Behavioral: The M.D. Anderson Symptom Inventory (MDASI)

First Posted Date: 2017-10-19

Last Posted Date: 2024-11-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT03315026

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy